share_log

The Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Adopted Negative Opinion On Approval Of Eisai/Biogen's Lecanemab As Treatment For Early Alzheimer's Disease, Eisai Said It Will Seek Re-Examination Of The Opinion

Benzinga ·  Jul 26 07:24

and work with the relevant authorities to ensure this treatment is available for eligible people living with early AD in the European Union (EU) as soon as possible.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment